Patents Examined by Sagar Patel
  • Patent number: 12152022
    Abstract: Anti-viral active agents, particularly the free base hemihydrate form of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide, as well as methods for the manufacture thereof. Also the use of the above compound in the treatment of human herpes virus infections and in the preparation of pharmaceuticals comprising said compound.
    Type: Grant
    Filed: April 2, 2021
    Date of Patent: November 26, 2024
    Assignee: AICURIS ANTI-INFECTIVE CURES GMBH
    Inventors: Yogeshwar Bachhav, Wilfried Schwab, Alexander Birkmann, Kurt Voegtli
  • Patent number: 12138253
    Abstract: Provided is a method for preventing, ameliorating, suppressing the progression of, and/or treating a tumor caused by a tumor virus, the method including the step of administering, to a subject, an effective amount of a component that targets a gene product of the tumor virus.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: November 12, 2024
    Assignee: KYOTO UNIVERSITY
    Inventors: Masatoshi Hagiwara, Masahiko Ajiro, Tetsunori Sakamoto
  • Patent number: 12134614
    Abstract: The present invention relates to solid forms of the insecticide of formula I: compositions comprising the solid forms and methods of their use as insecticides.
    Type: Grant
    Filed: May 10, 2021
    Date of Patent: November 5, 2024
    Assignee: SYNGENTA CROP PROTECTION AG
    Inventors: Ian Kevin Jones, John Hone, Neil George
  • Patent number: 12091396
    Abstract: A method of producing tetrahydrocannabinolic acid (THCA), the method includes obtaining a starting compound, the starting compound being selected from the group consisting of delta 9-THC, delta 8-THC, and delta 10-THC; placing the starting compound into a high pressure reaction chamber; treating the starting compound with a high heat, a high pressure, and carbon dioxide within the high pressure reaction chamber to create a resulting product; and treating the resulting product with sulfuric acid to yield the THCA.
    Type: Grant
    Filed: October 7, 2021
    Date of Patent: September 17, 2024
    Inventor: Adam Woodson
  • Patent number: 12083101
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Grant
    Filed: March 15, 2021
    Date of Patent: September 10, 2024
    Assignee: Novartis AG
    Inventors: Vincent Bordas, Cara Brocklehurst, Patrick Chene, Pascal Furet, Vito Guagnano, Patricia Imbach-Weese, Joerg Kallen, Mickael Le Douget, Edwige Liliane Jeanne Lorthiois, Joseph McKenna, Bahaa Salem, Tobias Schmelzle, Holger Sellner, Nicolas Soldermann, Markus Voegtle, Markus Wartmann
  • Patent number: 12076405
    Abstract: This invention provides heterocyclic compounds that bind to E3 Ubiquitin Ligase (typically through cereblon) (“Degrons”), which can be used as is or linked to a Targeting Ligand for a selected Target Protein for therapeutic purposes and methods of use and compositions thereof as well as methods for their preparation.
    Type: Grant
    Filed: February 1, 2021
    Date of Patent: September 3, 2024
    Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Mark E. Fitzgerald, Minsheng He, Ryan E. Michael
  • Patent number: 12070469
    Abstract: The present disclosure related to compositions, methods, dosages, dosage regimens, articles of manufacture and kits for the treatment and/or prevention ectopic calcifications, and in particular cutaneous calcifications such as calciphylaxis calcifications comprising inositol phosphate, inositol phosphate analogs, inositol phosphate derivatives, or combinations thereof. In a particular aspect the disclosure provides a dosage regimen to treat calciphylaxis comprising the administration of 6 mg/kg to 9 mg/kg daily doses of myo-inositol hexaphosphate, three times a week, for at least 1 to 8 months.
    Type: Grant
    Filed: March 4, 2021
    Date of Patent: August 27, 2024
    Assignee: SANIFIT THERAPEUTICS S.A.
    Inventors: Joan Perello Bestard, Carolina Salcedo Roca, Ana-Zeralda Canals Hamann
  • Patent number: 12059412
    Abstract: One aspect of the present disclosure relates to a pharmaceutical composition, containing (R)-N-[1-(3,5-difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide as a first ingredient and containing a vinylpyrrolidone-based polymer as a second ingredient. The composition of one aspect of the present disclosure has a formulation characteristic in which the crystal formation of a compound represented by chemical formula 1 is delayed for a long time.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: August 13, 2024
    Assignee: Amorepacific Corporation
    Inventors: Joonho Choi, Wonkyung Cho, Jong Hwa Roh, Kwanghyun Shin, Byoung Young Woo, Min Soo Kim, Miyoung Park, Youngho Park, Eunsil Park, Jaehong Park, Kiwha Lee
  • Patent number: 12053441
    Abstract: The present disclosure concerns methods and formulations for delivery of hydrophobic agents (such as ubiquinone or poorly soluble drugs) for therapeutic and bioanalytical use. It further concerns use of lipopeptides (e.g. caspofungin) or surfactants to solubilize hydrophobic agents and thus increase their bioavailability. Also described are therapeutic methods for the treatment of conditions that benefit from such hydrophobic agents. The present disclosure further relates to methods of identifying drug candidates for treatment of ubiquinone deficiency.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: August 6, 2024
    Assignee: THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY
    Inventors: Siegfried Hekimi, Ying Wang
  • Patent number: 12054490
    Abstract: The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.
    Type: Grant
    Filed: August 16, 2023
    Date of Patent: August 6, 2024
    Assignees: Gilead Sciences, Inc., Carna Biosciences, Inc.
    Inventors: Masaaki Sawa, Mai Arai, Ryoko Nakai, Hirokazu Matsumoto, Jonathan William Medley, Leena Patel, Qingming Zhu, Tetsuya Kobayashi
  • Patent number: 12017995
    Abstract: The present invention relates to crystalline forms of the free base of the c-Met inhibitor, Compound 1. The invention also relates to crystalline forms of salts of Compound 1. The invention also relates to pharmaceutical compositions comprising the solid polymorphs of the free base and salts of Compound 1. The invention further relates to methods of treating a disease, disorder, or syndrome mediated at least in part by modulating in vivo activity of a protein kinase.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: June 25, 2024
    Assignee: Exelixis, Inc.
    Inventors: Frenel DeMorin, Khalid Shah, Sagar Shakya, Peter Wong, Courtney S. Johnson, Melanie Janelle Bevill, Stephan D. Parent
  • Patent number: 12006283
    Abstract: Disclosed are a novel hypoxia-inducible factor 1? (HIF-1?) inhibitor, a method of preparing the same, and a pharmaceutical composition for preventing or treating an angiogenesis-related eye disease containing the same as an active ingredient. The compound of Example provided according to an embodiment of the present invention is capable of effectively inhibiting HIF-1? and is thus useful as a pharmaceutical composition for preventing or treating an angiogenesis-related eye disease.
    Type: Grant
    Filed: August 12, 2019
    Date of Patent: June 11, 2024
    Assignee: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: Youngger Suh, Seungbeom Lee, Jeonghun Kim
  • Patent number: 11999738
    Abstract: A chemical entity of Formula (I): wherein V, W, Y, and Z, have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, cognitive disorders, neurodegenerative diseases, and trauma-dependent losses of function; enhancing the efficiency of cognitive and motor training, including in stroke or TBI rehabilitation; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, dermatological, inflammatory, and pain disorders.
    Type: Grant
    Filed: April 15, 2021
    Date of Patent: June 4, 2024
    Assignee: Dart NeuroScience, LLC
    Inventors: Laurent Gomez, William Francois Vernier
  • Patent number: 11999677
    Abstract: Benzylamino-oxoethyl benzamide compounds for use in treating diseases and conditions associated with abnormal cell function related to endoplasmic reticulum (ER) stress. For example, the compounds can be used as suppressors of ER stress-induced pancreatic ?-cell dysfunction and death, for example in the treatment of Type 1 and Type 2 diabetes. The compounds can also be used in treatments for chronic heart disease, neurodegenerative diseases, retinal degeneration, and other metabolic disorders associated with ER stress.
    Type: Grant
    Filed: February 8, 2022
    Date of Patent: June 4, 2024
    Assignee: The Board of Regents of the University of Oklahoma
    Inventors: Weidong Wang, Venkateswararao Eeda
  • Patent number: 11992478
    Abstract: Provided herein are methods of treating cancer in a subject with a ZIP9 inhibitor. In certain embodiments, the cancerous tissues do not express the nuclear androgen receptor (AR). These methods, alone or in combination with other cancer therapies, can improve treatment outcomes in patients suffering from cancer, particularly male patients.
    Type: Grant
    Filed: February 19, 2021
    Date of Patent: May 28, 2024
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Todd Ridky, Christopher Natale, Cristina Aguirre Portoles
  • Patent number: 11993572
    Abstract: The present invention relates to a composition which comprises an electron-transporting host and a hole-transporting host, to the use thereof in electronic devices and to electronic devices containing this composition. The electron-transporting host is particularly preferably selected from the class of the lactams. The hole-transporting host is preferably selected from the class of the biscarbazoles.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: May 28, 2024
    Assignee: Merck Patent GmbH
    Inventors: Amir Parham, Jonas Kroeber, Tobias Grossmann, Anja Jatsch, Christian Eickhoff, Christian Ehrenreich
  • Patent number: 11963960
    Abstract: This invention relates to compounds for treating acute myeloid leukemia or inhibiting recurrence of acute myeloid leukemia and for inhibiting growth of and/or killing leukemic stem cells.
    Type: Grant
    Filed: March 15, 2021
    Date of Patent: April 23, 2024
    Assignee: Flash Therapeutics, LLC
    Inventors: Michael Serrano-Wu, Zhixiong Ye, Kejia Ding
  • Patent number: 11964941
    Abstract: Disclosed herein are compositions and methods for treating cancer, FLT3-AML, and CML.
    Type: Grant
    Filed: July 6, 2020
    Date of Patent: April 23, 2024
    Assignee: City of Hope
    Inventors: Sangkil Nam, David Horne, Jun Xie
  • Patent number: 11932611
    Abstract: An 3-(5-(3-fluorophenyl)-4-phenyl-4H-1,2,4-triazol-3-ylthio)propanoic acid compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: October 18, 2023
    Date of Patent: March 19, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • Patent number: 11905244
    Abstract: Methods of identification of inhibitors of calcium release-activated calcium (CRAC) channel and small molecule inhibitors of CRAC channel, including methods of their synthesis and pharmaceutical use, are disclosed.
    Type: Grant
    Filed: September 18, 2020
    Date of Patent: February 20, 2024
    Assignee: The Texas A&M University System
    Inventors: Yubin Zhou, Lian He